Subchronic oral toxicity study of Habb-e-Suranjan in albino Wistar rats

Khalid Ghazanfar; Showkat A Dar; Tazeen Nazir; Seema Akbar

doi:10.1515/jcim-2017-0144

Article

Subchronic oral toxicity study of Habb-e-Suranjan in albino Wistar rats

Khalid Ghazanfar , Showkat A Dar , Tazeen Nazir and Seema Akbar

Published/Copyright: March 28, 2018

Published by

Become an author with De Gruyter Brill

Submit Manuscript Author Information Explore this Subject

From the journal Journal of Complementary and Integrative Medicine Volume 15 Issue 3

Abstract

Background

Habb-e-Suranjan (HS) is a Unani pharmacopoeial formulation used for treatment of rheumatoid arthritis. The present study was carried to evaluate the toxic potential of HS in albino Wistar rats.

Methods

The subchronic was carried out at the dose levels of 2440 mg/kg of body weight in both sexes. The rats were observed carefully for any behavioral change for next 24 hours (hr) after the administration of the drug and daily twice thereafter till the completion of experimentation. Water/feed consumption and body weight were recorded on weekly basis. The rats were sacrificed on 91st day after overnight fasting. Blood was collected for hematological and biochemical analysis. The rats were dissected and organs were observed for any morphological changes. Organ samples were collected for histological studies.

Results

There were no incidences of mortality/morbidity found in any of the treated rats. HS caused no significant difference in the body weights as well as relative organs weights of treated groups when compared with the control groups. There were no significant changes found in any biochemical, hematological and histopathological parameters that could indicate any signs of toxicity.

Conclusions

The study suggests that HS is safe and did not induce any adverse effect in rats.

Keywords: Habb-e-Suranjan; histopathology; physiological parameters; subchronic toxicity

Acknowledgments

Authors are thankful to the Director General, Central Council for Research in Unani Medicine, New Delhi, India for providing necessary infrastructure to carry out the work. The authors are grateful to Science and Engineering Research Board, New Delhi (SERB) for providing the N-PDF fellowship (NPDF File No.PDF/2016/003266) to one of authors. The authors are highly thankful to Department of Science and Technology (DST), GoI, New Delhi for funding the project entitled ―Establishment of National Facility for Non Clinical Safety Evaluation of Unani Drugs‖ at RRIUM, Srinagar. We also pay gratitude to Mr Ashaq Ahmad Bhat, Mr Bashir Ahmad Bhat and Mr Shafiq Ahmad Khan for their valuable contribution in animal handling and the maintenance of animal house.

Author contributions: Seema Akbar and Showkat A Dar conceived and designed the experiments; Tazeen Nazir and Showkat A Dar performed the experiments; analyzed the data; contributed reagents/materials/analysis tools; Khalid Ghazanfar wrote the paper.
Research funding: None declared.
Employment or leadership: None declared.
Honorarium: None declared.
Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.

References

[1] Rudra S, Kalra A, Kumar A, Joe W. Utilization of alternative systems of medicine as health care services in India: evidence on AYUSH care from NSS 2014. PLoS One. 2017;12:e0176916. doi:10.1371/journal.pone.0176916.Search in Google Scholar PubMed PubMed Central

[2] Yesilada E. Contribution of traditional medicine in the healthcare system of the Middle East. Chin Integr Med. 2011;17:95–8. DOI: 10.1007/s11655-011-0651-0.Search in Google Scholar PubMed

[3] Poulakou-Rebelakou E, Karamanou M, George A. The impact of ancient Greek medicine in India: the birth of Unani medicine. Acta Medico-Historica Adriatica. 2015;13:323–8.Search in Google Scholar

[4] Hongal S, Torwane NA, Pankaj G, Chandrashekhar BR, Gouraha A. Role of Unani system of medicine in management of orofacial diseases: a review. J Clin Diagn Res. 2014;8:ZE12–5. doi:10.7860/JCDR/2014/8335.5018.Search in Google Scholar PubMed PubMed Central

[5] Khalid G, Da SA, Seema A, Tazeen N, Mariya H, Khalid MS, et al. Safety evaluation of Unani formulation: capsule Shaqeeqa in albino Wistar rats. Scientifica. 2016;2016:Article ID 2683403.10.1155/2016/2683403Search in Google Scholar PubMed PubMed Central

[6] Rodrigues E, Barnes J. Pharmacovigilance of herbal medicines: the potential contributions of ethnobotanical and ethnopharmacological studies. Drug Saf. 2013;36:1–12.10.1007/s40264-012-0005-7Search in Google Scholar PubMed

[7] Shaw D, Graeme L, Pierre D, Elizabeth W, Kelvin C. Pharmacovigilance of herbal medicine. J Ethnopharmacol. 2012;140: 513–8.10.1016/j.jep.2012.01.051Search in Google Scholar PubMed

[8] Stickel F1, Egerer G, Hk S. Hepatotoxicity of botanicals. Public Health Nutr. 2000;3:113–24.10.1017/S1368980000000161Search in Google Scholar PubMed

[9] Teschke R, Wolff A, Frenzel C, Schulze J. Eickhoff A Herbal hepatotoxicity: a tabular compilation of reported cases. Liver Int. 2012;32:1543–56.10.1111/j.1478-3231.2012.02864.xSearch in Google Scholar PubMed

[10] Teschke R, Genthner A, Wolff A, Frenzel C, Schulze J, Eickhoff A. Herbal hepatotoxicity: analysis of cases with initially reported positive re-exposure tests. Dig Liver Dis. 2014;46:264–9.10.1016/j.dld.2013.10.020Search in Google Scholar PubMed

[11] Bunchorntavakul C, Reddy KR. Review article: herbal and dietary supplement hepatotoxicity. Aliment Pharmacol Ther. 2013;37:3–17.10.1111/apt.12109Search in Google Scholar PubMed

[12] Wendell C, Marian N, Austin C, June HK. Effects of herbal supplements on the kidney. Urol Nurs. 2005;25:381–6.Search in Google Scholar PubMed

[13] Mohammad A. A brief study of toxic effects of some medicinal herbs on kidney. Adv Biomed Res. 2012;1. DOI: 10.4103/2277–9175.100144Search in Google Scholar PubMed

[14] Allard T, Wenner T, Greten HJ, Efferth T. Mechanisms of herb-induced nephrotoxicity. Curr Med Chem. 2013;20:2812–9.10.2174/0929867311320220006Search in Google Scholar PubMed

[15] Ernst E. Serious psychiatric and neurological adverse effects of herbal medicines – a systemic review. Acta Psychiatr Scand. 2003;108:83–91.10.1034/j.1600-0447.2003.00158.xSearch in Google Scholar

[16] Miotto K, Iguchi M, Hilton L, Shekelle P. A multidisciplinary approach to the toxicologic problems associated with the use of herbal medicines. Expert Opin Drug Saf. 2005;4:879–84.10.1517/14740338.4.5.879Search in Google Scholar

[17] Neergheen-Bhujun VS. Underestimating the toxicological challenges associated with the use of herbal medicinal products in developing countries. Biomed Res Int. 2013;2013:Article ID 804086.10.1155/2013/804086Search in Google Scholar PubMed

[18] Dwivedi S, Aggarwal A, Sharma V. Cardiotoxicity from ‘safe’ herbomineral formulations. Trop Doct. 2011;41:113–5.10.1258/td.2010.100304Search in Google Scholar PubMed

[19] Maffe S, Paffoni P, Laura CM, Davanzo F, Dellavesa P, Cucchi L, et al. Herbs and cardiotoxic effects. G Ital Cardiol. 2013;14:445–55.Search in Google Scholar

[20] Gromek K, Drumond N, Simas P. Pharmacovigilance of herbal medicines. Int J Risk Saf Med. 2015;27:55–65.10.3233/JRS-150643Search in Google Scholar PubMed

[21] Khalid G, Showkat AD, Tazeen N, Irfat A, Akbar M and Seema A. Safety evaluation of polyherbal Unani formulation –deedan in Wistar rats. J Appl Pharm Sci. 2015;5:089–93.Search in Google Scholar

[22] CCRUM. National formulary of Unani medicine Vol. Part I-1. New Delhi: AYUSH, 2006:33.Search in Google Scholar

[23] Surender S, Vinod N, Gupta YK. Antiarthritic activity of Majoon Suranjan (a polyherbal Unaniformulation) in rat. Indian J Med Res. 2011;134:384–8.Search in Google Scholar PubMed

[24] Mythily S, Shagufta Y, Rafat SA, Vinod KA, Asok KT, Db B. Evaluation of therapeutic efficacy of Majoon Suranjan, a Unani formulation, in the treatment of rheumatoid arthritis: an experimental study. Exp Biol Med (Maywood). 2013;238:1379.10.1177/1535370213498983Search in Google Scholar PubMed

[25] OECD. Test No. 408: repeated dose 90-day oral toxicity study in rodents, OECD guidelines for the testing of chemicals, section 4. Paris: OECD Publishing, 1998.Search in Google Scholar

[26] Skalli S, Soulaymani Bencheikh R. Safety monitoring of herb-drug interactions: a component of pharmacovigilance. Drug Saf. 2012;35:785–91.10.1007/BF03261975Search in Google Scholar PubMed

[27] Meincke R, Pokladnikova J, Straznicka J, Meyboom RHB, Niedrig D, Russmann S, et al. Allergy-like immediate reactions with herbal medicines in children: a retrospective study using data from VigiBase. Pediatric Allergy Immunol. 2017. DOI: 10.1111/pai.12778Search in Google Scholar

[28] Schilter B, Andersson C, Anton R. Guidance for the safety assessment of botanicals and botanical preparations for use in food and food supplements. Food Chem Toxicol. 2003;41:1625–49.10.1016/S0278-6915(03)00221-7Search in Google Scholar PubMed

[29] Hilaly JE, Israili ZH, Lyoussi B. Acute and chronic toxicological studies of Ajuga iva in experimental animals. J Ethnopharmacol. 2004;91:43–50.10.1016/j.jep.2003.11.009Search in Google Scholar PubMed

[30] Olson H, Betton G, Robinson D. Concordance of the toxicity of pharmaceuticals in humans and in animals. Regul Toxicol Pharmacol. 2000;32:56–67.10.1006/rtph.2000.1399Search in Google Scholar PubMed

[31] Singh A, Bhat TK, Sharma OP. Clinical biochemistry of hepatotoxicity. J Clinic Toxicol. 2011;S4:001. DOI: 10.4172/2161-0495.S4-001Search in Google Scholar

[32] Yang X, Laura KS, Qiang S, William FS. Hepatic toxicity biomarkers. Chapter 13. USA: Elsevier, 2014:241–59.10.1016/B978-0-12-404630-6.00013-0Search in Google Scholar

[33] Devarbhavi H. An update on drug-induced liver injury. J ClinExp Hepatol. 2012;2:247–59.10.1016/j.jceh.2012.05.002Search in Google Scholar

[34] Van-Meer L, Moerland M, Cohen AF, Burggraaf J. Urinary kidney biomarkers for early detection of nephrotoxicity inclinical drug development. Br J Clin Pharmacol. 2014;77:947–57.10.1111/bcp.12282Search in Google Scholar

[35] Gowda S, Desai PB, Kulkarni SS, Hull VV, Mathm AAK, Vernekar SN. Markers of renal function tests. North Am J Med Sci. 2010;2:170–3.Search in Google Scholar

[36] FucHS TC, Hewitt P. Biomarkers for drug-induced renal damage and nephrotoxicity – an oan overview for applied toxicology. Am Assoc Pharm Scientists. 2011;13:615–31.10.1208/s12248-011-9301-xSearch in Google Scholar

[37] Barger AM. The complete blood cell count: a powerful diagnostic tool. Vet Clin America Small Anim. 2003;33:1207–22.10.1016/S0195-5616(03)00100-1Search in Google Scholar

[38] Vinay K, Abul A, Jon A. Lymph nodes and spleen. In: Wb S, editor. Robbins Basic Pathology, 8th ed. Philadelphia: Elsevier, 2017.Search in Google Scholar

[39] Ramakrishna N, K G V, Santanu J, Santosh KP and Anil G. What suits best for organ weight analysis: review of relationship between organ weight and body/brain weight for rodent toxicity studies. Internat J Pharml Sci Res. 2014;5:1525–32.Search in Google Scholar

[40] Michael B, Yano B, Sellers RS, Perry R, Morton D, Roome N, et al. Evaluation of organ weights for rodent and non-rodent toxicity studies: a review of regulatory guidelines and a survey of current practices. Toxicol Pathol. 2007;35:742–50.10.1080/01926230701595292Search in Google Scholar PubMed

Received: 2017-10-27

Accepted: 2018-02-20

Published Online: 2018-03-28

You are currently not able to access this content.

Articles in the same Issue

https://doi.org/10.1515/jcim-2017-0144

Keywords for this article

Habb-e-Suranjan; histopathology; physiological parameters; subchronic toxicity